Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Trial Identifier: TED14856
Sponsor: Sanofi
Start Date: September 2017
Primary Completion Date: November 2024
Study Completion Date: November 2024
Condition: Breast Cancer

Trial Locations

Country Location
BELGIUM LEUVEN, BELGIUM, 3000
CANADA, Alberta EDMONTON, Alberta, CANADA, T6G 1Z2
CANADA, British Columbia VANCOUVER, British Columbia, CANADA, V5Z 1L3
CANADA, Ontario TORONTO, Ontario, CANADA, M4N 3M5
CZECHIA BRNO, CZECHIA, 656 53
CZECHIA PRAGUE, CZECHIA, 128 08
CZECHIA PRAGUE, CZECHIA, 140 59
FRANCE BORDEAUX, FRANCE, 33076
FRANCE LILLE, FRANCE, 59000
FRANCE LYON, FRANCE, 69373
FRANCE SAINT-HERBLAIN, FRANCE, 44805
FRANCE VILLEJUIF, FRANCE, 94805
ITALY, Milano MILAN, Milano, ITALY, 20141
POLAND, Pomorskie GDYNIA, Pomorskie, POLAND, 81-519
PORTUGAL LISBON, PORTUGAL, 1649-035
PORTUGAL LISBON, PORTUGAL, 1998-018
SPAIN, Madrid MADRID, Madrid, SPAIN, 28034
SPAIN, Madrid MADRID, Madrid, SPAIN, 28050
SPAIN, Madrid MADRID, Madrid, SPAIN, 28041
UNITED KINGDOM, Cardiff [Caerdydd GB-CRD] CARDIFF, Cardiff [Caerdydd GB-CRD], UNITED KINGDOM, CF14 2TL
UNITED KINGDOM, Oxfordshire OXFORD, Oxfordshire, UNITED KINGDOM, OX3 7LE
UNITED STATES, Colorado AURORA, Colorado, UNITED STATES, 80045
UNITED STATES, Massachusetts BOSTON, Massachusetts, UNITED STATES, 02114
UNITED STATES, New York NEW YORK, New York, UNITED STATES, 10065
UNITED STATES, Washington SEATTLE, Washington, UNITED STATES, 98109